Used in the treatment of osteoporosis, this antibody targets sclerostin to promote bone formation. It increases bone mineral density and reduces fracture risk in postmenopausal women and other high-risk patients. Currently under clinical development, it offers a promising anabolic approach for severe bone loss conditions.